SML0131
ABT-751 hydrochloride
≥98% (HPLC)
别名:
N-[2-[(4-Hydroxyphenyl)amino]-3-pyridyl]-4-methoxybenzenesulfonamide hydrochloride
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H17N3O4S · HCl
化学文摘社编号:
分子量:
407.87
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
产品名称
ABT-751 hydrochloride, ≥98% (HPLC)
InChI
1S/C18H17N3O4S.ClH/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13;/h2-12,21-22H,1H3,(H,19,20);1H
SMILES string
Cl.COc1ccc(cc1)S(=O)(=O)Nc2cccnc2Nc3ccc(O)cc3
InChI key
KWQWWUXRGIIBAS-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
pink to purple
solubility
DMSO: ≥15 mg/mL
originator
Abbott
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
ABT-751 is an orally bioavailable vascular disrupting agent (VDA) with a broad spectrum of antitumor activity. It binds to the colchicine binding site on β-tubulin and inhibits polymerization of microtubules.
ABT-751, a sulfonamide antimitotic agent, is under clinical trials to treat patients with various malignancies including refractory hematologic malignancies, non-small cell lung cancer (NSCLC), and colon cancer.
Orally bioavailable vascular disrupting agent (VDA) that binds to the colchicine binding site on β-tubulin and inhibits polymerization of microtubules; broad spectrum of antitumor activity.
Features and Benefits
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Timothy J Jorgensen et al.
Cancer chemotherapy and pharmacology, 59(6), 725-732 (2006-09-13)
ABT-751 is an orally active antimitotic agent that is currently in Phase II clinical trials. This agent binds to the colchicine site on ss-tubulin and inhibits polymerization of microtubules. This disruption of microtubule dynamics leads to a block in the
Karen W L Yee et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 11(18), 6615-6624 (2005-09-17)
ABT-751 is an oral antimitotic agent that binds to the colchicine site on beta-tubulin. A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory
Tian Ma et al.
Chemotherapy, 58(4), 321-329 (2012-11-14)
ABT-751 is a novel antimitotic agent that exerted cytotoxic effects in preclinical studies. Carboplatin has efficacy in treating advanced non-small cell lung cancer (NSCLC) in combination with other drugs. Lung cancer cell lines were treated with ABT-751 and/or carboplatin to
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持